Centers for Medicare & Medicaid Services
7500 Security Boulevard
145 articles with Centers for Medicare & Medicaid Services
Dynanet is a CMS ACME BPA Awardee
The Centers for Medicare & Medicaid Services has awarded Dynanet a Prime contract to provide services under the Agile Collaboration and Modernization Endeavors Blanket Purchase Agreement.
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
Harrow today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.
McKesson Designated by CMS as 2023 Qualified Clinical Data Registry
For the seventh consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
MicroTransponder Secures CMS Transitional Pass-Through Status & New Technology Add-On Payment for Its Breakthrough Stroke Rehabilitation System, Vivistim
MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services awarded the Vivistim® Paired VNS™ System transitional pass-through status, expanding access to Medicare beneficiaries who are ischemic stroke survivors interested in using the breakthrough technology to help improve their hand and arm mobility.
EvoEndo Announces Ambulatory Payment Classification (APC) Reassignments for Flexible Transnasal Esophagogastroduodenoscopy (EGD)
EvoEndo ® , Inc. (“EvoEndo”), a medical device company developing systems for Unsedated Transnasal Endoscopy (TNE), is pleased to share recent decisions announced by the Centers for Medicare and Medicaid Services (CMS) in its CY 2023 Hospital Outpatient Prospective Payment System (OPPS) final rule.
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
Arch Therapeutics, Inc. today announced that the Centers for Medicare and Medicaid Services (“CMS”) has made a preliminary recommendation to establish a dedicated Healthcare Common Procedure Coding System (“HCPCS”) Level II billing code specific to AC5 ® Advanced Wound System (“AC5”).
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
Neovasc Inc. announced that the Centers for Medicare and Medicaid Services has assigned the Neovasc Reducer™ implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.
EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23
EDAP TMS SA, the global leader in robotic therapeutic ultrasound, announced that the U.S. Centers for Medicare and Medicaid Services has released its final outpatient prospective payment system reimbursement rule for calendar year 2023, which becomes effective on January 1st.
Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d test
Immunovia AB announced, that the Centers for Medicare & Medicaid Services published a preliminary payment determination implying a price of $897 for the IMMray PanCan-d test.
AAOS Comments on Proposed Medicare Payment Policy Changes for 2023
The American Association of Orthopaedic Surgeons issued formal comments to the Centers for Medicare & Medicaid Services on the agency's proposed payment policy changes for Calendar Year 2023.
Vascular Quality Initiative (SVS VQI) Announces the Expansion of Medicare Coverage to Standard Surgical Risk Patients within their TCAR Surveillance Project
The Society for Vascular Surgery® Vascular Quality Initiative®, a nonprofit organization dedicated to improving the quality of vascular care within hospitals and outpatient facilities, announces that the Centers for Medicare and Medicaid Services has expanded coverage for Transcarotid Artery Revascularization to include standard surgical risk patients within the VQI TCAR Surveillance Project.
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
American Lung Association: CMS Announcement Will Increase Access to Lifesaving Lung Cancer Screening
Centers for Medicare and Medicaid Services announced that it updated its lung cancer screening eligibility guidelines for people covered by Medicare to be similar to the U.S.
CMS issued a draft decision for Biogen’s Alzheimer’s drug and said it would only cover the cost of Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
McKesson Designated by CMS as 2022 Qualified Clinical Data Registry
For the sixth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Biogen and its partner Eisai Company released additional details about the Phase IV post-marketing study of the drug.
It’s a landmark no one expected or wanted — more than 70 million confirmed COVID-19 cases in the U.S. with 866,000 deaths. For that and more COVID-19 news, continue reading.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”